A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium difficile toxin A), MK-6072 (Human Monoclonal Antibody to

Project: Other project

StatusFinished
Effective start/end date12/1/1211/1/14

Funding

  • Merck Sharp & Dohme Corporation: $21,197.00